Viloxazine — Qelbree — is the newer non-stimulant option for ADHD, approved in 2021. The mechanism is selective norepinephrine reuptake inhibition combined with some serotonergic modulation (5-HT2C agonism, 5-HT2B antagonism). Mechanistically related to atomoxetine but not identical.
- Class
- Selective norepinephrine reuptake inhibitor (NRI)
- Mechanism
- NET reuptake inhibition + serotonergic modulation (5-HT2C agonism, 5-HT2B antagonism — modulator profile)
- Typical dose
- 100-400 mg/day (children/adolescents); 200-600 mg/day (adults)
- Half-life
- ~7 hours
- FDA indications
- ADHD (children, adolescents, adults)
- Key adverse effects
- Somnolence, decreased appetite, fatigue, irritability, headache, modest BP/HR elevation, possible mood symptoms
Black box: Suicidal ideation (class effect for non-stimulant ADHD medications)
Recently approved (2021). Alternative to atomoxetine when atomoxetine fails or causes side effects. Once-daily dosing. Drug interactions: significant CYP1A2 inhibition (raises caffeine, theophylline levels). Cost is constraint.
Clinical position: second-line non-stimulant. The patient who has tried atomoxetine without adequate benefit, or who couldn't tolerate atomoxetine's side effects, is the typical viloxazine candidate. The dosing is once-daily, which is a meaningful convenience over the BID dosing some atomoxetine patients use.
The CYP1A2 inhibition is the distinctive practical concern. Viloxazine is a substantial CYP1A2 inhibitor, which means co-administered 1A2 substrates accumulate. Affected drugs include caffeine, theophylline, duloxetine, melatonin, clozapine. Drug interaction screening at every prescription is essential. Patients on viloxazine become more caffeine-sensitive — counsel that the morning coffee may hit harder.
Other side effects: somnolence (often initial), decreased appetite, fatigue, irritability, modest BP/HR elevation. Class warning for suicidality applies as with atomoxetine. Long-term safety data are still accumulating compared to atomoxetine's longer track record.
Viloxazine is a newer non-stimulant ADHD agent — like atomoxetine a noradrenergic reuptake inhibitor, but with additional serotonergic receptor activity.
Mechanism note: Viloxazine is a second non-stimulant noradrenergic option with added serotonergic activity — a useful alternative to atomoxetine when a non-controlled agent is needed.
Cost is the constraint. Viloxazine is brand-only and expensive. Insurance coverage varies; prior authorization is common. For the patient who needs it specifically — atomoxetine inadequate, stimulants contraindicated, daily-dosing convenience required — viloxazine is a reasonable option when access permits. For most non-stimulant first-line use, atomoxetine remains the default starting point.
- Cost
- Brand-only Qelbree: ~$400/month.
- Generic status
- No generic.
- Formulary typical
- Specialty tier with PA.
- Access friction
- PA often requires failed atomoxetine trial. Manufacturer support program for commercial patients.
Prescriber tip: Second-line non-stimulant. For atomoxetine non-responders or intolerators, viloxazine PA usually goes through on that rationale.